Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADAPT

Financiado

Cerrado

Adipokines as Drug Targets to Combat Adverse Effects of Excess Adipose Tissue

Obesity represents the major risk factor for the cardiometabolic syndrome, which is an epidemic disease that generates a severe global socio-economic burden for the public health systems. Enhanced production of proinflammatory adi... ver más

31/01/2012

UDUS

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2012-01-31 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

UDUS

0.00€ | Lider

STOCKHOLMS UNIVERSITET

N.D. | Participante

CHARITE UNIVERSITAETSMEDIZI...

N.D. | Participante

Proyectos interesantes

ADIBET

Medical Technol...

Data Science

1M€ Cerrado

TOBI

Medical Technol...

Data Science

4M€ Cerrado

REPROBESITY

Medical Technol...

Data Science

7M€ Cerrado

FATarget

Medical Technol...

Data Science

183K€ Cerrado

SiCMetabol

Medical Technol...

Data Science

1M€ Cerrado

ADIPOR

Medical Technol...

Applied Physics

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Obesity represents the major risk factor for the cardiometabolic syndrome, which is an epidemic disease that generates a severe global socio-economic burden for the public health systems. Enhanced production of proinflammatory adipocytokines by expanded adipose tissue is now considered as a key event in the pathogenesis of this syndrome. This process involves i) the systemic release of adipokines, preferentially by visceral abdominal fat and ii) the paracrine, adipokine-mediated crosstalk between periorganic fat and different organs including skeletal and cardiac muscle. Members of the ADAPT consortium have pioneered this novel view of adipose tissue as an active endocrine organ. However, there is very limited knowledge if adipokines and their downstream signalling pathways may represent drugable targets potentially opening new avenues to combat the devastating complications linked to obesity and the cardiometabolic syndrome. Therefore, the major goal of this project is to identify novel or existing adipocytokines as drug targets that could be used to reverse obesity-associated inflammation and adverse reactions related to excess fat, as outlined in the work programme. For this purpose the mustidisciplinary ADAPT consortium has been formed which integrates basic and clinical science, bioinformatics, in silico drug design and the specific expertise of a large pharmaceutical company. To reach the objectives, a stepwise strategy will be used including i) the identification of novel adipocytokines and the cellular sources and regulation of adipokine production, ii) the analysis of intraorgan crosstalk within adipose tissue which plays a pivotal role in adipose tissue inflammation, iii) the assessment of interorgan crosstalk with a focus on skeletal and cardiac muscle and the role of brown fat and iv) the pharmacological and clinical evaluation of adipokines as drug targets and potential biomarkers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores